Related Experiment Video

Updated: Sep 3, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and

Kristen I Barton1, Riley J Boyle, Douglas A Dennis

  • 1From the Colorado Joint Replacement (Barton, Boyle, Dennis, Jennings), AdventHealth, Denver, School of Physical Therapy (Barton), Western University, London, Canada, the Department of Mechanical and Materials Engineering (Dennis, Jennings), University of Denver, Denver, Department of Orthopaedics (Dennis), University of Colorado School of Medicine, Denver, Department of Biomedical Engineering (Dennis), University of Tennessee, Knoxville, TN, Department of Physical Therapy (Jennings), University of Delaware, Newark, DE.

The Journal of the American Academy of Orthopaedic Surgeons
|September 1, 2026
PubMed

Keywords:
glucagon-like peptide 1 receptor agonistslower extremity arthroplastyoptimizationtotal hip and knee arthroplastytotal joint arthroplasty

More Related Videos

Treatment of Ankle Osteoarthritis with Total Ankle Replacement Through a Lateral Transfibular Approach09:01

Treatment of Ankle Osteoarthritis with Total Ankle Replacement Through a Lateral Transfibular Approach

Published on: January 24, 2018

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...